Autoimmune & Rheumatology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

This Phase 3 trial is testing a new injectable medicine called NNC0487-0111 for people who have extra body weight and knee osteoarthritis. If the medicine is effective, it could provide a new way to help reduce both weight and knee pain, which are often linked. The study is recruiting participants in several countries and will provide important information about how safe and effective this treatment might be.

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

This Phase 3 trial is focused on children aged 5 to under 18 who have moderate to severe systemic lupus erythematosus, also known as lupus. The study is testing intravenous anifrolumab to see if it can better control the disease alongside standard lupus treatments. Successful results could offer a new treatment option for children living with lupus, potentially improving their quality of life. The trial is currently recruiting at many sites worldwide.

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines

This study is testing the drug zasocitinib in adults with psoriatic arthritis, a condition that affects joints and skin. It includes people who have previously used biologic medicines as well as those who have not. The trial aims to find a new treatment that can reduce joint pain and skin symptoms, offering hope for better management of this chronic condition. The study is recruiting participants globally and will last up to 60 weeks.

Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet

This Phase 2 trial is investigating a combination of nandrolone, physiotherapy, and diet to treat sarcopenia, which is muscle loss often seen in older adults. The study includes participants aged 60 to 99 with confirmed muscle weakness. If successful, this approach could help improve muscle strength and physical fitness, potentially enhancing independence and daily functioning. The trial is recruiting in Poland.

Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis

This Phase 2 trial is testing olokizumab, a biologic medicine, in children and adolescents aged 2 to under 18 with juvenile idiopathic arthritis. The goal is to see if this treatment can improve symptoms and help control the disease in young patients. The trial is currently recruiting in Russia and could provide a new option for families managing this condition.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.